Second Opinion

Clinical Investigators Provide Their Perspectives on Challenging Cases and Controversies in the Management of Multiple Myeloma

CME INFORMATION

TARGET AUDIENCE

This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of multiple myeloma (MM).

OVERVIEW OF ACTIVITY

It is estimated that approximately 148,040 new lymphoid and myeloid cancer cases will be identified in the United States in the year 2012, and 65,900 individuals will die from these diseases. Importantly, there are currently over 45 drug products labeled for use in the management of hematologic malignancies, comprising more than 55 distinct FDA-approved indications. While this extensive list of available treatment options is reassuring for patients and oncology healthcare professionals, it poses quite a challenge to the practicing clinician who must maintain up-to-date knowledge of appropriate clinical management strategies across a vast spectrum of liquid and solid tumors.

These proceedings from a case-based CME symposium combine the perspectives of 5 renowned investigators on a number of controversial issues in the diagnosis and treatment of MM with a review of emerging research information in this area to assist medical oncologists, hematology-oncology fellows and other healthcare providers as they attempt to formulate optimal disease management strategies in the face of a constantly evolving body of knowledge.

LEARNING OBJECTIVES

- Integrate the results of emerging clinical research into the selection of optimal systemic therapy for patients with MM who are eligible and ineligible for stem cell transplant.
- Use biomarkers to assess risk for patients with MM, and recommend systemic treatment commensurate with prognosis and likelihood of therapeutic response.
- Compare and contrast patient outcomes with lenalidomide- and bortezomib-based induction therapy, and consider the role of combined immunomodulatory and proteasome inhibitor regimens.
- Communicate the benefits and risks of postinduction maintenance therapy to appropriately selected patients with MM.
- Recognize treatment-associated side effects, and offer patients acceptable alternative dosing/administration and/or supportive management interventions to address them.
- Evaluate the safety profiles and response outcomes observed in studies of next-generation proteasome inhibitors and immunomodulatory agents for patients with MM.
- Counsel appropriately selected patients with MM about participation in ongoing clinical trials investigating novel therapeutic agents and strategies.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this enduring material for a maximum of 0.75 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity consists of a video component. To receive credit, the participant should watch the video, complete the Post-test with a score of 70% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/SecondOpinionMM13/CME.

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the

RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

Rafael Fonseca, MD
Getz Family Professor of Cancer
Chair, Department of Internal Medicine
Mayo Clinic Arizona
Scottsdale, Arizona

Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genzyme Corporation, Intellikine, Lilly, Medtronic Inc, Millennium: The Takeda Oncology Company, Otsuka Pharmaceutical Co Ltd; **Research Support:** Celgene Corporation, Onyx Pharmaceuticals Inc.

Sagar Lonial, MD
Professor
Vice Chair of Clinical Affairs
Director of Translational Research, B-Cell Malignancy Program
Department of Hematology and Medical Oncology
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Advisory Committee and Consulting Agreements: Bristol-Myers Squibb Company, Celgene Corporation, Lilly, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Sanofi.

Paul G Richardson, MD
Associate Professor of Medicine
Harvard Medical School
Clinical Director of the Jerome Lipper
Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Advisory Committee: Bristol-Myers Squibb Company, Celgene Corporation, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation.

A Keith Stewart, MBChB
Dean for Research, Mayo Clinic in Arizona
Consultant, Division of Hematology/Oncology
Vasek and Anna Maria Polak Professorship in Cancer Research
Scottsdale, Arizona

Advisory Committee: Amgen Inc, Celgene Corporation; **Consulting Agreements:** Celgene Corporation, Millennium: The Takeda Oncology Company; **Contracted Research:** Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc.

Ravi Vij, MD
Associate Professor of Medicine
Washington University School of Medicine
Section of Stem Cell Transplant and Leukemia
Division of Medical Oncology
St Louis, Missouri

Consulting Agreements: Abbott Laboratories, Bristol-Myers Squibb Company, Celgene Corporation, Onyx Pharmaceuticals Inc; **Contracted Research:** Celgene Corporation, Onyx Pharmaceuticals Inc; **Speakers Bureau:** Celgene Corporation, Cephalon Inc, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc.

EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Algeta US, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Oncology.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Millennium: The Takeda Oncology Company and Onyx Pharmaceuticals Inc.

Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Last review date: December 2013

Expiration date: December 2014

SELECT PUBLICATIONS

Arnulf B et al. **Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma.** *Haematologica* 2012;97(12):1925-8.

Attal M et al. **Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.** *N Engl J Med* 2012;366(19):1782-91.

Boccadoro M et al. **Melphalan/prednisone/lenalidomide (MPR) versus high-dose melphalan and autologous transplantation (MEL200) in newly diagnosed multiple myeloma (MM) patients: A phase III trial.** *Proc ASCO* 2011;**Abstract 8020**.

Bringhen S et al. **Efficacy and safety of once weekly bortezomib in multiple myeloma patients.** *Blood* 2010;116(23):4745-53.

Dimopoulos MA et al. **Pomalidomide in combination with low-dose dexamethasone: Demonstrates a significant progression free survival and overall survival advantage, in relapsed/refractory MM: A phase 3, multicenter, randomized, open-label study.** *Proc ASH* 2012;**Abstract LBA-6**.

Fostier K et al. **Carfilzomib: A novel treatment in relapsed and refractory multiple myeloma.** *Onco Targets Ther* 2012;5:237-44.

Jakubowiak AJ et al. **A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.** *Blood* 2012;120(9):1801-9.

Lendvai N et al. **Phase II study of infusional carfilzomib in patients with relapsed or refractory multiple myeloma.** *Proc ASH* 2012;**Abstract 947**.

Lonial S et al. **Phase I study of twice-weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients (pts) with relapsed and/or refractory multiple myeloma (MM).** *Proc ASCO* 2012;**Abstract 8017**.

McCarthy PL et al. **Lenalidomide after stem-cell transplantation for multiple myeloma.** *N Engl J Med* 2012;366(19):1770-81.

Moreau P et al. **Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: A randomised, phase 3, non-inferiority study.** *Lancet Oncol* 2011;12(5):431-40.

Moreau P et al. **A phase 3 prospective randomized international study (MMY-3021) comparing subcutaneous and intravenous administration of bortezomib in patients with relapsed multiple myeloma.** *Proc ASH* 2010;**Abstract 312**.

Palumbo A et al. **Carfilzomib, cyclophosphamide and dexamethasone (CCd) for newly diagnosed multiple myeloma (MM) patients.** *Proc ASH* 2012;**Abstract 730**.

Palumbo A, Anderson K. **Multiple myeloma.** *N Engl J Med* 2011;364(11):1046-60.

Rajkumar SV. **Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management.** *Am J Hematol* 2011;86(1):57-65.

Reeder CB et al. **Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma.** *Blood* 2010;115(16):3416-7.

Richardson PG et al. **Oral weekly MLN9708, an investigational proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients (pts) with previously untreated multiple myeloma (MM): A phase I/II study.** *Proc ASCO* 2012;**Abstract 8033**.

Richardson PG et al. **Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.** *Blood* 2010;116(5):679-86.

Siegel DS et al. **A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.** *Blood* 2012;120(14):2817-25.

Singhal S et al. **Integrated safety from Phase 2 studies of monotherapy carfilzomib in patients with relapsed and refractory multiple myeloma (MM): An updated analysis.** *Proc ASH* 2011;**Abstract 1876**.